25,858 Shares in Supernus Pharmaceuticals, Inc. $SUPN Acquired by PDT Partners LLC

PDT Partners LLC bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 25,858 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,203,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sit Investment Associates Inc. boosted its position in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock worth $3,240,000 after purchasing an additional 250 shares during the period. Summit Global Investments increased its holdings in Supernus Pharmaceuticals by 6.1% in the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock valued at $229,000 after purchasing an additional 256 shares during the last quarter. Maryland State Retirement & Pension System raised its position in Supernus Pharmaceuticals by 3.6% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock valued at $415,000 after purchasing an additional 290 shares during the period. SummitTX Capital L.P. raised its position in Supernus Pharmaceuticals by 2.7% in the fourth quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after purchasing an additional 303 shares during the period. Finally, PNC Financial Services Group Inc. lifted its stake in Supernus Pharmaceuticals by 2.3% during the first quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after purchasing an additional 321 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald lifted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Trading Down 1.1%

Shares of SUPN opened at $44.88 on Thursday. Supernus Pharmaceuticals, Inc. has a twelve month low of $42.45 and a twelve month high of $59.68. The firm’s fifty day simple moving average is $46.83 and its 200-day simple moving average is $48.74. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -23.37, a PEG ratio of 0.84 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business’s revenue for the quarter was up 32.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.40 EPS. On average, analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.